Hbs Ag

The HBs Ag test detects the presence of the hepatitis B surface antigen and indicates active HBV infection. It becomes positive in the early phase of infection and plays a critical role in assessing the level of contagiousness. It provides rapid and reliable diagnostic information for clinical management.

Measurement of HBs Ag levels provides important information in distinguishing acute from chronic infection. Antigen intensity contributes to the assessment of viral activity and guides the clinician in determining the frequency of follow-up. In this way, monitoring strategies can be planned appropriately.

HBs Ag screening during pregnancy aims to detect maternal HBV infection and prevent vertical transmission. Early detection allows timely administration of neonatal prophylaxis and reduces the risk of neonatal complications related to hepatitis B. Screening occupies a key place in national health policies.

HBs Ag monitoring helps early detection of infection in high-risk groups. Regular screening enables identification of chronic carriers, supports decisions regarding the need for antiviral therapy, and contributes to controlling chains of transmission in the community.

What Is HBs Ag?

HBs Ag (Hepatitis B surface antigen) is a protein located on the surface of the Hepatitis B virus (HBV) and indicates that a person is actively carrying a Hepatitis B infection. If HBs Ag is positive in the blood, the individual is infectious and may be in the acute or chronic phase of the infection. It is a fundamental test in the diagnosis, screening and assessment of transmission risk for Hepatitis B. Positive results should be supported with further investigations.

What is the Hepatitis B virus and how does it affect the body?

Hepatitis B is a virus that primarily targets the liver. Once it enters the body, there are two possible scenarios. The first is an “acute,” that is, new infection. Most healthy adults (90–95%) clear the virus completely within six months with a strong immune response and gain lifelong immunity. Many people go through this phase so mildly that they mistake it for a simple flu, or do not even notice it.

However, in some cases, especially when the immune system fails to clear the virus, the HBsAg test remains positive for longer than six months. This condition is called “chronic Hepatitis B” infection. The virus settles in the liver cells and may remain silent or gradually damage the liver over time.

From the standpoint of IVF treatment, the most critical point is this: The risk of chronic infection is directly related to the age at which the virus is acquired. While the risk is 5–10% when an adult becomes infected, the risk of chronic infection can be as high as 90% in a newborn who acquires the virus during delivery from the mother. These babies have a very high lifetime risk of serious liver diseases (cirrhosis, liver cancer). For this reason, throughout the IVF and pregnancy process, our main goal is to prevent transmission of the virus to the baby at all costs.

What does HBsAg positivity mean?

The presence of HBsAg (Hepatitis B surface antigen) in your blood is definitive evidence that the virus is currently in your body. It shows that the virus is present in your blood and body fluids and that you can potentially transmit it to others.

A positive result in this test is the “alarm” sign that activates all safety protocols in the IVF process. As soon as this result is obtained, a more detailed plan should immediately be implemented to obtain a complete picture of the situation for both you and your partner and, most importantly, to protect your future baby. Although rare, this test may be temporarily “falsely positive” in the first weeks after receiving a Hepatitis B vaccine, so when interpreting the test, it is also important to ask whether you have been vaccinated recently.

Why are Anti-HBs and Anti-HBc tests, in addition to HBsAg, important?

• HBsAg positivity is only the beginning of the story. To fully understand your relationship with the virus (whether it is new, old, whether you are immune), two more tests are needed:
• Anti-HBs (or HBsAb): This is your “protective shield.” It is the protective antibody that your body produces against Hepatitis B. The presence of this antibody (above a certain level) in your blood shows that you are safe against the virus, in other words, that you are immune. This immunity can be acquired in two ways: either you have encountered the virus in the past and defeated the disease (natural immunity), or you have completed a successful vaccination schedule (vaccine-induced immunity).
• Anti-HBc Total (or HBcAb): This is a somewhat more complex but very important marker. It is produced against the “core” of the virus. The most important feature is that this antibody is not formed by vaccination. A positive result shows that your body has at some point encountered the “real” virus. It is not protective; it is merely a sign of “exposure.”

By looking at the combination of these three tests (HBsAg, Anti-HBs, Anti-HBc), it can be clearly determined whether a person is susceptible (never exposed), protected by vaccination, immune after past infection, or currently an active or chronic carrier.

How are acute and chronic Hepatitis B infections distinguished?

When HBsAg is positive, the first question that must be answered is: Is this a new (acute) infection, or a condition that has lasted for more than six months (chronic)? This distinction is very important because, if the infection is recent, the body has a high chance of clearing the virus on its own, and in this situation, postponing IVF treatment may be the most logical option.

To make this distinction, a special test called IgM Anti-HBc is used. This test is a marker of a “fresh” infection. If this test is positive, your infection has most likely occurred within the last six months (acute). If it is negative, this strongly suggests that you are a chronic (long-term) carrier.

Why are HBeAg and HBV DNA (viral load) tests so critical in the management of Hepatitis B?

Once we understand that you are a chronic Hepatitis B carrier, we need to know the “character” of the virus. In other words, is the virus “dormant,” or is it “active” and replicating rapidly?

• HBeAg (Hepatitis B e antigen): This test is a marker that shows the virus is actively replicating and that your level of contagiousness is very high. HBeAg positivity usually means that the amount of virus in the blood is also high.
• HBV DNA (Viral Load): This is currently the most important test in the management of Hepatitis B, particularly in pregnancy planning. Unlike serological tests, it does not simply say “present/absent”; it counts how many viruses are present in one milliliter of your blood (in IU/mL). In other words, it measures the “quantity” of the virus.

The reason this test is critical is as follows: The amount of virus in the mother’s blood (viral load) is the number one factor determining the risk of transmission to the baby. If the mother’s viral load is very high (the generally accepted threshold is 200,000 IU/mL), the standard protection given to the baby at birth (vaccine + immunoglobulin) may sometimes be insufficient. Pregnant women whose viral load exceeds this threshold are started on antiviral drugs that are safe to use in pregnancy during the last trimester (between weeks 28 and 32) to rapidly lower the viral load. In this way, the amount of virus the baby is exposed to at birth decreases and the success of protection at delivery rises to 95–99%.

How does HBsAg positivity affect male reproductive health?

Yes, there is growing evidence that chronic Hepatitis B infection may have some adverse effects on male reproductive potential. It is thought that the virus does not remain confined only to the liver, but can also affect the reproductive organs.

Studies show that HBsAg positive men tend to have certain problems in sperm health. Some observed effects include:

• Low sperm concentration
• Reduced sperm motility
• Impaired sperm morphology (shape)
• Increased sperm DNA damage (fragmentation)

Sperm DNA damage, in particular, is an important factor that can lead to fertilization failure, slowing or arrest of embryo development, and even early pregnancy loss (miscarriage).

Why can IVF/ICSI treatment still be successful when the man has Hepatitis B?

Despite these potential negative effects on sperm quality, there is very reassuring information for couples undergoing IVF: Large-scale studies have shown that HBsAg positivity in the father does not affect live birth rates in IVF treatment (especially ICSI).

How can this apparent contradiction be explained? The answer lies in the power of the modern IVF laboratory.

• Sperm Washing: In the laboratory, the semen sample is processed using special “washing” techniques. This procedure removes the seminal plasma, where the virus is concentrated, as well as unhealthy and immotile sperm.
• Intracytoplasmic Sperm Injection (ICSI): Even more importantly, in the ICSI method, the embryologist selects under the microscope a single sperm with the best motility and most normal morphology from among millions and injects it directly into the egg.

In other words, even if the virus has damaged part of the sperm population, laboratory technology can “overcome” this problem by identifying and using the best sperm to create a healthy embryo.

Does HBsAg positivity affect female fertility and ovarian reserve?

Although this topic has been studied more recently than the male factor, unfortunately it appears that similar concerns may apply to women as well. The virus may also have a direct negative effect on the female reproductive system.

The most striking findings suggest that chronic Hepatitis B infection may be associated with a reduced “ovarian reserve.” Ovarian reserve is an indicator of both the number and quality of eggs in a woman’s ovaries.

In HBsAg positive women, some differences have been observed compared with other women of the same age:

• Lower AMH (Anti-Müllerian Hormone) levels
• Lower antral follicle count (AFC) on ultrasound examination
• Need for higher doses of medications to stimulate the ovaries in IVF treatment
• Fewer mature oocytes retrieved

The likely reason is that the chronic, low-grade inflammation induced by the virus in the ovarian tissue may cause the ovaries to “age” biologically faster. This finding is an important recommendation that women with chronic Hepatitis B should avoid excessively delaying their plans to have children.

Does Hepatitis B in the woman affect IVF success or miscarriage risk?

Beyond the potential reduction in egg numbers, the quality of the retrieved eggs and subsequent embryos may also be affected. Some studies have shown that in HBsAg positive women, fertilization rates and the rate of obtaining good-quality (high-grade) embryos may be lower.

The impact on clinical outcomes is even more important. Several studies have reported that HBsAg positivity in the mother may somewhat reduce implantation rates (the embryo’s ability to attach to the uterus) and unfortunately may statistically increase the risk of early miscarriage. Some publications indicate that this risk may almost double compared with the healthy population. This may be due both to decreased developmental potential of the embryo owing to impaired egg quality and to disruption of immune balance in the endometrium (uterine lining) caused by the virus, which can make implantation more difficult.

Why should all couples be screened for Hepatitis B before IVF?

When embarking on a complex and valuable process such as IVF, the first rule is “safety.” For this reason, regardless of whether they have risk factors, all couples (both the woman and the man) who apply to the clinic must be screened for blood-borne infections (Hepatitis B, Hepatitis C, HIV). This is an international requirement.

The purpose of this “universal screening” is to identify infected individuals from the outset and to take all necessary precautions to protect them, their partners, their future babies, the embryos of other patients in the laboratory, and the healthcare team.

What are the first steps when HBsAg positivity is detected?

When we encounter a positive HBsAg result, a comprehensive evaluation is immediately initiated to clarify the situation and draw a safe roadmap. The steps taken in this process are:

• Completing the full serology panel (Anti-HBs, Anti-HBc, IgM Anti-HBc)
• Tests of viral activity (HBeAg, Anti-HBe)
• Quantitative HBV DNA (viral load) measurement
• Liver function tests (ALT, AST)
• Full Hepatitis B panel screening of the partner

What is the role of the Infectious Diseases or Hepatology specialist in Hepatitis B follow-up?

Managing the IVF process of an HBsAg positive patient is not solely the work of an IVF specialist; it is a team effort. Every patient with chronic Hepatitis B should be evaluated by an Infectious Diseases or Gastroenterology (Hepatology) specialist before starting IVF treatment.

This mandatory consultation has several purposes. The specialist evaluates the patient’s overall liver health. They decide whether antiviral therapy is needed, not only for pregnancy, but also for the patient’s long-term health. They monitor the course of the virus during and after pregnancy and take precautions against possible flares. The decision to “start” IVF treatment is made jointly with this specialist.

What is the approach when one partner is HBsAg positive and the other negative (serodiscordant couple)?

This is one of the most common and most clearly managed scenarios. Such a situation is called a “serodiscordant” couple (serologically mismatched). Here the primary priority is to protect the uninfected, “susceptible” partner (that is, a partner whose HBsAg, Anti-HBs and Anti-HBc tests are negative).

The steps are clear: A Hepatitis B vaccination schedule is immediately started for the uninfected partner. IVF treatment is postponed until the vaccination series (usually three doses given at months 0, 1 and 6) is completed. During this period, the couple must use barrier methods, such as condoms, during sexual intercourse.

One to two months after completion of the vaccination series, the blood is tested to determine whether the protective antibody (Anti-HBs) level has reached an adequate value (>10 mIU/mL). Once adequate protection is confirmed, the risk of horizontal transmission between partners disappears and IVF treatment can begin safely. This is a non-negotiable rule.

What special laboratory procedures are performed on the sperm of an HBsAg positive man?

When the father-to-be is HBsAg positive, the semen sample he provides undergoes a special and meticulous procedure in the laboratory. This procedure is known as “sperm washing.”

This process is performed using multi-layer density gradient techniques or swim-up methods that utilize sperm motility. The goal is to separate the healthy, motile, and morphologically normal sperm from the seminal plasma, in which virus particles, inflammatory cells, and dead sperm are concentrated. This dramatically reduces the amount of virus in the final sperm sample used for fertilization (IVF or ICSI).

Does sperm washing completely eliminate the risk of Hepatitis B?

This is a very important point: Sperm washing is a method of “risk reduction,” not a method of “risk elimination.”

Why? Because although washing very effectively removes free virus in the seminal fluid, there is a possibility that viral DNA may be integrated into the genetic material (chromosomes) of some sperm cells. No current laboratory technique can distinguish a sperm cell that has viral DNA integrated into it.

For exactly this reason, in couples where the man is HBsAg positive, it is mandatory, before starting treatment, that the female partner is vaccinated and has developed immunity (Anti-HBs positive). The woman’s immune system provides the main and final protection against this very low, theoretical risk that may remain even after sperm washing, thus giving us “double security.”

What safety measures are taken in the IVF lab for HBsAg positive samples?

One of the most feared scenarios in the IVF laboratory is “cross-contamination,” meaning transmission of virus from the eggs, sperm, or embryos of one patient to the samples of another. To prevent this, very strict rules, in line with international standards, are applied.

These rules are designed to protect both the samples of other patients and the laboratory staff. Some of the measures include:

• Full adherence to universal infection control precautions
• Processing infected patients’ samples in dedicated biological safety cabinets
• Using separate devices (centrifuges, incubators, etc.) for these procedures whenever possible
• Scheduling procedures at times separate from other patients’ procedures (for example, at the end of the day)
• Ensuring that all laboratory staff are vaccinated against Hepatitis B and use appropriate protective equipment (gloves, gowns, goggles)

What is important when freezing (cryopreserving) embryos of HBsAg positive patients?

The freezing process involves storing embryos or gametes (sperm/eggs) in liquid nitrogen (–196 °C). Theoretically, if a damaged freezing container leaks in the same liquid nitrogen tank, there is a risk that virus could spread to another patient’s sample.

To eliminate even this theoretical risk, embryos of HBsAg positive patients (and those with other blood-borne infections) are stored in cryotanks that are physically completely separate and specially labeled from the tanks containing other patients’ samples. This provides complete isolation and safe long-term storage with zero risk.

What treatment is used to prevent transmission to the baby in HBsAg positive pregnant women?

Whether pregnancy occurs through IVF or naturally, the follow-up of an HBsAg positive mother requires special attention. The process is coordinated between the obstetrician and the infectious disease specialist.

In the third trimester of pregnancy (the last three months, usually between weeks 28 and 32), the amount of virus in the mother’s blood (HBV DNA) is re-measured. If this viral load is above the critical threshold of 200,000 IU/mL, the mother is started on an antiviral medication (usually Tenofovir) to actively reduce the risk of transmission to the baby.

The use of this drug during pregnancy is considered very safe and does not harm the baby. The goal of treatment is not to cure the mother, but to reduce the viral load as much as possible before delivery, so that the protective vaccine and immunoglobulin administered to the baby at birth are maximally effective.

Does the mother’s Hepatitis B carrier status affect the mode of delivery or breastfeeding?

You can be completely reassured on this point. The answers to both questions are clear:

Mode of Delivery: No, it does not. There is no scientific evidence that cesarean section reduces the risk of Hepatitis B transmission to the baby compared with vaginal delivery. HBsAg positivity alone is not an indication for cesarean section. The mode of delivery will be determined by your obstetrician based on the course of your pregnancy.

Breastfeeding: No, it is not contraindicated. As long as the baby receives the necessary protective interventions (vaccine and immunoglobulin) immediately after birth, breastfeeding is absolutely safe and recommended. This is also true for mothers who receive antiviral therapy during pregnancy; they can safely continue breastfeeding.

What is the “Critical 12 Hours” rule to protect babies born to mothers with Hepatitis B?

The time of birth and the immediate postpartum period are the most critical moments when we are racing against the clock to protect the baby. Every baby born to an HBsAg positive mother must receive two important, life-saving interventions within the “first 12 hours after birth.” Missing this 12-hour window greatly reduces the chance of protecting the baby from lifelong chronic infection.

The dual protection administered to the baby within this critical period includes:

• Hepatitis B Immune Globulin (HBIG)
• Hepatitis B Vaccine (First Dose)

HBIG is a serum containing “ready-made protective antibodies” given from outside. It provides immediate passive protection against any virus that may have entered the baby’s body. The vaccine is administered to activate the baby’s own immune system and to provide long-term active protection. These two injections are usually given at the same time in different legs.

Thanks to this dual protection (and, if necessary, antiviral treatment of the mother during pregnancy), the baby’s protection rate against infection exceeds 95%.

How do we know that the baby is protected from Hepatitis B and has developed immunity?

After your baby receives initial protection at birth, the routine childhood vaccination schedule continues (usually at 1 or 2 months and at 6 months).

After the vaccination series is completed, usually when the baby is 9–12 months old (or 1–2 months after the last dose), a blood test is performed to determine whether all these measures have been successful. This test checks HBsAg and Anti-HBs levels.

• If the baby’s HBsAg is negative and Anti-HBs is positive, this is excellent news: The baby is not infected and has responded to the vaccine and is protected.
• If HBsAg is positive, unfortunately this means that, despite all the measures, protection has failed and the baby is infected (a rare situation).
• If both are negative, the baby is not infected but has also not responded to the vaccine (revaccination is required).

HBsAg positivity is a condition that requires extra steps and greater care on your journey to parenthood, but thanks to modern medical approaches and meticulous laboratory protocols, it is not an insurmountable barrier. With comprehensive diagnosis, close collaboration with Infectious Diseases specialists, mandatory vaccination of the susceptible partner, and proactive management of pregnancy and delivery to protect the baby, the process can be managed safely. The main goal is not only to achieve pregnancy, but also to complete this journey in the safest way for all involved and to welcome a healthy baby into your family who is protected from Hepatitis B.

Frequently Asked Questions